[Relapse of chronic myeloid leukemia presenting with blurred vision after allogeneic hematopoietic stem cell...

A 34-year-old man underwent unrelated bone marrow transplantation (BMT) for blast-phase chronic myeloid leukemia (CML). Molecular remission was achieved on day 29. Around day 600 after BMT, the patient developed blurred vision in the right eye. Peripheral blood major mRNA was undetectable on day 606. An ophthalmologic examination on day 613 identified circumferential iris thickening and anterior chamber hypopyon-like lesions in the right eye. Betamethasone and levofloxacin ophthalmic solutions were started on the same day. On day 624, the white lesion in the anterior chamber had resolved, but iris thickening persisted. On day 663, peripheral blood major BCR::ABL1 mRNA (IS) increased as well, and molecular relapse of CML was diagnosed. Dasatinib was started at 20 mg/day on day 6 after relapse, and blurred vision improved on day 10 after relapse. On day 27 after relapse, the white lesion in the anterior chamber and iris hyperplasia had also resolved. By day 147 after relapse, dasatinib was gradually increased to 100 mg/day. Molecular remission was achieved on day 161 after relapse. Three years later, the patient remains in remission on dasatinib therapy.